From population health to personalised insight—Antidote Analytics is reshaping the future of clinical decision-making.
BMI is Broken. The Consequences Are Global.
BMI misclassifies a substantial proportion of patients—sometimes up to 50%—leading both to unnecessary treatments and missed opportunities for early intervention. Liver fat, a key driver of conditions such as NAFLD and NASH, remains significantly under-diagnosed, with around 75% of cases going undetected. Standard frontline tools lack sensitivity, while advanced options like FibroScan and MRI are expensive and not accessible at scale. At the same time, health systems worldwide face growing financial pressure from the rising prevalence of obesity, Type 2 diabetes, and fatty liver disease.
75%
Liver Fat Under-diagnosis
50%
BMI Misclassification
Meet BCI — Body Composition, Reimagined
Antidote Analytics has developed a breakthrough AI-driven metric, BCI (Body Composition Index) — the first scalable replacement for BMI. BCI accurately predicts visceral, subcutaneous, and liver fat using easy-to-measure inputs, delivering clinically meaningful data with no scans, hardware, or behavioural input required.
This core technology has the potential to become the default health risk indicator across healthcare, insurance, pharma, and wellness — where BMI currently dominates but underperforms.
About Antidote Analytics
Antidote Analytics exists to eliminate blind spots in health assessment. We build tools that give clinicians, researchers, and insurers the insight they need to make faster, smarter decisions.
Antidote Analytics is the research arm of Antidote Holdings. Analytics is headed by Dr Errol Richardson and Adrian Povey.
Our Team
Errol Richardson PhD-
Chief Executive Officer
Errol has been involved in health and wellbeing for 25 years.
He began his career as a fitness instructor before moving into freelance personal training. As his knowledge deepened, he became increasingly aware that much of the fitness industry was built on flawed or outdated science. This led him back to university, where he studied nutritional biochemistry at the University of Nottingham, graduating with a first and finishing top of his year.
He went on to pursue a PhD at Imperial College London in the lab that discovered the appetite-lowering effects of GLP-1, the compound behind many of today’s weight-loss drugs. Errol’s research focused on how the brain senses glucose and regulates appetite and blood sugar levels. His research uncovered a potential mechanism that may explain why some people have a “sweet tooth”, and crave carbohydrate — work that was published in multiple high impact academic journals and featured in the mainstream media.
Following this, Errol worked in Imperial’s Division of Women’s Health, where his research explored how poor nutritional environments in the womb can increase a person’s risk of developing type 2 diabetes, heart disease, and other chronic conditions in adulthood.
In 2013, he co-founded The Health Concierge with Nick Buckley, a fellow researcher he met during his PhD. Their shared vision was to bring scientific rigour to the wellness space.
In 2021, they launched Antidote LDN — a company designed to bring evidence-based wellness to a broader audience, with a mission to build the first recognisable brand in the corporate health sector.
Adrian Povey FCA -
Non Executive Chairman
Adrian is a successful entrepreneur and company director, combining large, quoted company experience with start-up knowledge and skills.
He has been a CEO and Group Finance Director in both quoted and private companies across a number of sectors, focussed on Mergers and Acquisitions and adding long term value.
Over his career, Adrian has been involved in more than twenty acquisitions around the world, adding more than £100m in value to the businesses he worked in. In 2006 he set up a property management business, with a partner, growing it over the next fifteen years to become one of the country’s largest, before selling part of the business in 2020. He has worked with quoted groups, privately owned businesses and within the venture capital world.
Adrian’s experience in the healthcare sector extends over the several years he worked for Huntleigh Technology plc, an FTSE 350 international healthcare group, where he rose to Deputy Group FD responsible for its M&A operation together with investor relations. During this time, he worked closely with the NHS over Private Financing Initiative options.
He qualified as a Chartered Accountant before entering industry and became a Fellow of the Institute of Chartered Accountants in 2002. He has acted as a non- executive director in a number of SME businesses across various sectors.
Away from business, Adrian spends his time on time actively participating in a variety of sports.
Let’s Transform Clinical Insight Together
Whether you're a healthcare provider, insurer, or innovator—if you’re ready to move beyond BMI, we’d love to hear from you.